{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-046408","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.199223+00:00","generated_at":"2026-05-15T04:56:11.571559+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Incannex Healthcare PSX-001 aligns with Trump Executive Order accelerating psychedelic mental health treatments","bullets":["White House Executive Order (April 18, 2026) directs FDA to prioritize psychedelic compounds with Breakthrough Therapy designations and creates Right to Try pathways.","PSX-001 Phase 2 for GAD: 12.8-point HAM-A reduction vs 3.6 placebo (p<0.0001), 44% response rate, 27% remission rate, no serious adverse events.","Company has over $70M cash, no debt; active U.S. IND; views Executive Order as reducing regulatory and commercial risk for psilocybin class.","PSX-001 targets GAD affecting ~6.8M in U.S. and 280M globally; Phase 2 had single discontinuation across 73 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-046408","json":"https://secwatch.observer/filing/0001213900-26-046408.json","markdown":"https://secwatch.observer/filing/0001213900-26-046408.md","text":"https://secwatch.observer/filing/0001213900-26-046408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026046408/0001213900-26-046408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026046408/ea0287297-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:56:11.571559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}